Head-to-head · WeighScore
AM Rx vs Trimrose
The verdict
Trimrose takes it — 55.2/100 to 49.6/100.
Trimrose grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Trimrose (Trimrose Inc.) is a cash-pay telehealth platform for compounded GLP-1 weight loss, offered as a weekly injection or a daily oral option.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | Trimrose |
|---|---|---|
| WeighScore | 49.6/100 | 55.2/100 |
| Grade | C | C |
| Scorecard rank | #491 | #446 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #491 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #446 · C
Strengths
- Free, no-cost, no-obligation online eligibility quiz before any commitment
- Offers a choice of a weekly compounded GLP-1 injection or a daily oral option
- Fully online — assessment, provider review, and home delivery with ongoing support
Where it loses points
- Runs on the CareValidate white-label platform and isn't the medical provider itself — a support@carevalidate.com address is exposed on the site
- Pricing isn't shown publicly; the cost and the specific compounded molecule appear only after you complete the eligibility quiz
- The states served, pharmacy partner and any LegitScript/503A certification aren't disclosed on the public site
- Markets 'up to 22.5% of body weight' — a trial figure for branded tirzepatide, not a guaranteed or compounded-specific outcome
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.